Adicet Bio Inc expected to post a loss of 28 cents a share - Earnings Preview

ADICET Bio

10/03/2023 21:27

* Adicet Bio Inc  ACET.OQ   ACET.O  is expected to show a
rise in
quarterly revenue when it reports  results on March 13
(estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
111.3% increase in revenue to $11.556 million from $5.47 million
a year ago, according to the mean estimate from 9 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Adicet Bio Inc is
for a
loss of 28 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adicet Bio
Inc is
$27.5​, above​ its last closing price of $7.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.55       -0.53      -0.53     Met     -0.6
 Jun. 30 2022  -0.44       -0.45      -0.56     Missed  -23.1
 Mar. 31 2022  -0.24       -0.18      0.10      Beat    154.9​
 Dec. 31 2021  -0.25       -0.42      -0.47     Missed  -11.6
 ​​Sep.        -0.44       -0.44      -0.44     Met     0
 30 2021                                                
 Jun. 30 2021  -0.53       -0.53      -0.34     Beat    35.8​
 Mar. 31 2021  -0.43       -0.49      -0.82     Missed  -67.9
 Dec. 31 2020              -0.88      -0.46     Beat    47.7
 This summary was machine generated March 10 at 21:27 GMT.  All
figures in US dollars  unless otherwise stated